Alcohol-induced disorders

Summary

Alcohol-induced disorders (MONDO:0021699) is a disease and 8 clinical trials. Top therapeutic interventions include naltrexone, digoxin, and magnesium. A subtype of alcohol-related disorders — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	alcohol-induced disorders
Mondo ID	MONDO:0021699
MeSH	D020751
SNOMED CT	719848005
UMLS	C0236970
MedGen	65935
Is cancer (heuristic)	no

Also known as: alcohol induced disorders · alcohol-induced disorder

Disease family

This is a subtype of alcohol-related disorders. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › substance-related disorder › alcohol-related disorders › alcohol-induced disorders

Related subtypes (7): alcohol abuse, alcoholic psychosis, alcohol withdrawal delirium, Wernicke encephalopathy, alcohol dependence, alcohol sensitivity, acute, alcohol amnestic disorder

Subtypes (4): fetal alcohol spectrum disorder, alcoholic pancreatitis, alcoholic cardiomyopathy, alcoholic liver disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	4
PHASE4	2
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00325299	PHASE4	COMPLETED	Magnesium After Alcohol Withdrawal Treatment
NCT00568958	PHASE4	COMPLETED	Naltrexone for Heavy Drinking in Young Adults
NCT05014087	PHASE2	TERMINATED	Digoxin In Treatment of Alcohol Associated Hepatitis
NCT05023317	PHASE1	COMPLETED	Strengths-based Linkage to Alcohol Care (SLAC) for Hazardous Drinkers in Primary Care
NCT04234139	Not specified	ENROLLING_BY_INVITATION	Cohort/Ethics Study of Patients With Severe Alcoholic Hepatitis Undergoing Early Liver Transplantation
NCT05787106	Not specified	ACTIVE_NOT_RECRUITING	Role of Adverse Childhood Events and Rejection Sensitivity on Alcohol Use in Recently Withdrawn Individuals With Alcohol Use Disorder
NCT01829308	Not specified	COMPLETED	SBIRT Implementation for Adolescents in Urban Federally Qualified Health Centers
NCT03018990	Not specified	UNKNOWN	Alcohol Challenge On Liver and Gut Measured by Liver Vein Catheterization. A Pathophysiological Intervention Trial

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
NALTREXONE	4	3
DIGOXIN	4	1
MAGNESIUM	3	1